Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardenilimab Combined With Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06165380Phase 2Active, not recruiting
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Objective Response Rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06165380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165380.